• BeOne Medicines is presenting Phase 1 results at ESMO 2026 showing durable responses to BGB-B2033 in heavily pretreated liver cancer.
• Global registrational trials of BGB-B2033 in late-line hepatocellular carcinoma are planned by the end of 2026.
• BGB-58067 data presented October 23 showed activity against MTAP-deficient non-small cell lung cancer, including brain metastases.
• BG-C477 showed tumor responses in previously treated lung cancer with high CEA expression; updated results will be presented October 26.
• Both lung cancer programs are expected to advance toward late-stage development in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261024371247) on October 24, 2026, and is solely responsible for the information contained therein.